Mencevax™ ACWY

BIOLOGICAL5 trials

Sponsors

GlaxoSmithKline

Conditions

Infections, Meningococcal

Phase 2

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

CompletedNCT00356369

GlaxoSmithKlineInfections, Meningococcal

Start: 2006-12-23End: 2008-02-28Updated: 2018-07-03

Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

CompletedNCT00390143

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-02-28End: 2009-05-31Updated: 2016-10-25

Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612

CompletedNCT00427908

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-02-07End: 2007-12-03Updated: 2018-06-04

Phase 3

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

CompletedNCT00291343

GlaxoSmithKlineInfections, Meningococcal

Start: 2006-02-01End: 2007-03-15Updated: 2018-06-06

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects

CompletedNCT00464815

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-05-02End: 2008-09-10Updated: 2018-06-08

Related Papers

A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years

BMC Infectious Diseases2020-06-1811 citations

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age

Human Vaccines & Immunotherapeutics2020-06-0215 citations

1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS

Open Forum Infectious Diseases2019-10-01

2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS

Open Forum Infectious Diseases2019-10-01

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents

Human Vaccines & Immunotherapeutics2017-02-0224 citations

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents

Human Vaccines & Immunotherapeutics2016-05-065 citations

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine

Human Vaccines & Immunotherapeutics2015-11-1729 citations

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial

BMC Infectious Diseases2015-10-0635 citations

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.

2013-03-0532 citations